
  
    
      
        Background_NNP
        The_DT nuclear_JJ receptor_NN (_( NR_NNP )_) family_NN comprises_VBZ 48_CD
        structurally_RB related_VBN transcription_NN factors_NNS ,_, many_JJ of_IN which_WDT
        require_VBP their_PRP$ cognate_NN ligand_NN for_IN activity_NN [_NN 1_CD 2_CD 3_CD ]_NN ._. The_DT
        NRs_NNP regulate_VB transcription_NN by_IN binding_JJ to_TO response_NN elements_NNS
        in_IN the_DT promoters_NNS of_IN target_NN genes_NNS and_CC acting_VBG as_IN scaffolds_NNS
        for_IN the_DT assembly_NN of_IN large_JJ coactivator_NN and_CC corepressor_NN
        complexes_NNS [_NN 4_CD ]_NN ._. NR_NNP coactivators_NNS include_VBP the_DT p_NN 160_CD s_VBZ
        (_( including_VBG GRIP_NNP 1_CD /_NN TIF-_NNP 2_CD ,_, SRC-_NNP 1_CD and_CC AIB_NNP 1_CD /_NN ACTR_NNP /_NN pCIP_NN )_) ._. The_DT
        p_NN 160_CD s_VBZ enhance_VB transcription_NN by_IN binding_JJ histone_NN
        acetyl-transferases_JJ such_JJ as_IN p_NN 300_CD /_NN CBP_NNP and_CC pCAF_NN [_NN 5_CD ]_NN and_CC
        methyl-transferases_JJ such_JJ as_IN CARM_NNP 1_CD and_CC PRMT_NNP [_NN 6_CD ]_NN which_WDT ,_, in_IN
        turn_NN ,_, enhance_VB transcription_NN by_IN modification_NN of_IN chromatin_NN ._.
        Other_JJ NR_NNP coactivators_NNS include_VBP TRAP_NNP 220_CD [_NN 7_CD ]_NN ,_, which_WDT is_VBZ part_NN
        of_IN a_DT larger_JJR complex_JJ (_( TRAP_NNP /_NN DRIP_NNP /_NN SMCC_NNP /_NN mediator_NN )_) that_IN contacts_NNS
        the_DT basal_NN transcription_NN machinery_NN and_CC PGC-_NNP 1_CD [_NN 8_CD ]_NN ,_, a_DT cold_JJ
        inducible_JJ coactivator_NN that_IN binds_NNS CBP_NNP and_CC SRC-_NNP 1_CD and_CC proteins_NNS
        involved_VBN in_IN RNA_NNP processing_NN [_NN 9_CD ]_NN ._. NR_NNP corepressors_NNS include_VBP
        NR_NNP corepressor_NN (_( N-C_NNP oR_NN )_) and_CC silencing_VBG mediator_NN of_IN retinoid_NN
        and_CC thyroid_NN responsive_JJ transcription_NN (_( SMRT_NNP )_) [_NN 4_CD ]_NN ._. Both_DT
        N-C_NNP oR_NN and_CC SMRT_NNP repress_NNS transcription_NN ,_, at_IN least_JJS in_IN part_NN ,_, by_IN
        binding_JJ to_TO histone_NN de-acetylases_JJ (_( HDACs_NNP )_) either_CC directly_RB or_CC
        indirectly_RB through_IN other_JJ corepressor_NN complex_JJ components_NNS ._.
        Other_JJ known_VBN NR_NNP corepressors_NNS include_VBP RIP_NNP 140_CD [_NN 10_CD ]_NN ,_,
        Hairless_NNP [_NN 11_CD ]_NN ,_, short_JJ heterodimer_NN partner_NN (_( SHP_NNP )_) [_NN 12_CD ]_NN
        and_CC DAX_NNP [_NN 13_CD ]_NN ,_, and_CC receptor_NN specific_JJ corepressors_NNS such_JJ as_IN
        the_DT estrogen_NN receptor_NN (_( ER_NNP )_) interacting_VBG proteins_NNS REA_NNP and_CC
        HET-SAFB_NNP [_NN 14_CD 15_CD ]_NN ._.
        Generally_RB ,_, NR_NNP transcriptional_NN activity_NN is_VBZ dictated_VBN by_IN
        the_DT balance_NN between_IN coactivator_NN and_CC corepressor_NN
        recruitment_NN ,_, and_CC one_CD of_IN the_DT most_RBS important_JJ factors_NNS that_WDT
        influences_VBZ this_DT balance_NN is_VBZ the_DT absence_NN or_CC presence_NN of_IN
        agonist_NN ligands_NNS (_( reviewed_VBN in_IN [_NN 4_CD ]_NN )_) ._. Unliganded_NNP NRs_NNP such_JJ
        as_IN thyroid_NN (_( TRs_NNP )_) and_CC retinoid_NN receptors_NNS (_( RARs_NNP )_) bind_NN
        corepressors_NNS ,_, and_CC ligand_NN promotes_VBZ release_NN of_IN corepressor_NN
        and_CC subsequent_JJ binding_JJ of_IN coactivators_NNS ._. The_DT mechanism_NN of_IN
        this_DT coregulator_NN exchange_NN is_VBZ well_RB understood_VBN ._. NRs_NNP consist_VBP
        of_IN three_CD domains_NNS ,_, the_DT N-_NNP terminal_NN domain_NN (_( which_WDT contains_VBZ a_DT
        context-specific_JJ activation_NN function_NN AF-_NNP 1_LS )_) ,_, the_DT central_JJ DNA_NNP
        binding_JJ domain_NN (_( DBD_NNP )_) and_CC the_DT C-_NNP terminal_NN ligand_NN binding_JJ
        domain_NN (_( LBD_NNP )_) ,_, which_WDT contains_VBZ a_DT hormone-dependent_JJ activation_NN
        function_NN ,_, AF-_NNP 2_CD ._. The_DT unliganded_JJ LBD_NNP recognizes_VBZ hydrophobic_JJ
        motifs_NNS ,_, termed_VBD interaction_NN domains_NNS (_( IDs_NNP )_) ,_, which_WDT are_VBP
        reiterated_VBD three_CD times_NNS in_IN N-C_NNP oR_NN and_CC twice_RB in_IN SMRT_NNP and_CC
        conform_VB to_TO the_DT consensus_NN L_NNP /_NN IXXIIXXXL_NNP [_NN 4_CD ]_NN (_( see_VB also_RB [_NN 16_CD ]_NN
        )_) ._. By_IN contrast_NN ,_, the_DT liganded_JJ LBD_NNP binds_NNS shorter_JJR hydrophobic_JJ
        motifs_NNS termed_VBD NR_NNP boxes_NNS that_WDT are_VBP reiterated_VBD several_JJ times_NNS
        within_IN each_DT coactivator_NN and_CC conform_VB to_TO the_DT consensus_NN LXXLL_NNP ._.
        The_DT LBD_NNP utilizes_NNS a_DT large_JJ hydrophobic_JJ cleft_NN composed_VBN of_IN
        residues_NNS along_IN H_NNP 3_CD and_CC H_NNP 5_CD to_TO bind_NN IDs_NNP [_NN 17_CD ]_NN ,_, and_CC a_DT smaller_JJR
        hydrophobic_JJ cleft_NN that_WDT is_VBZ composed_VBN of_IN residues_NNS in_IN the_DT upper_JJ
        part_NN of_IN H_NNP 3_CD and_CC H_NNP 5_CD and_CC H_NNP 12_CD (_( and_CC corresponds_NNS to_TO AF-_NNP 2_LS )_) to_TO bind_NN
        NR_NNP boxes_NNS [_NN 18_CD ]_NN ._. Thus_RB ,_, agonists_NNS promote_VBP coregulator_NN
        exchange_NN by_IN promoting_VBG the_DT packing_NN of_IN H_NNP 12_CD over_IN the_DT lower_JJR
        part_NN of_IN the_DT ID_NNP binding_JJ region_NN ,_, an_DT event_NN that_WDT simultaneously_RB
        completes_VBZ the_DT coactivator_NN binding_JJ surface_NN ._. In_IN other_JJ cases_NNS ,_,
        however_RB ,_, the_DT balance_NN of_IN coactivator_NN and_CC corepressor_NN
        recruitment_NN is_VBZ regulated_VBN by_IN direct_JJ competition_NN for_IN the_DT AF-_NNP 2_CD
        surface_NN ,_, rather_RB than_IN ligand-dependent_JJ coregulator_NN exchange_NN ._.
        RIP_NNP 140_CD ,_, Hairless_NNP and_CC DAX_NNP possess_VBP NR_NNP boxes_NNS that_WDT interact_NN
        with_IN AF-_NNP 2_CD [_NN 11_CD 13_CD 19_CD ]_NN and_CC these_DT corepressors_NNS act_VBP as_IN
        negative_JJ regulators_NNS of_IN the_DT activity_NN of_IN the_DT liganded_JJ NR_NNP ._.
        The_DT NR_NNP family_NN contains_VBZ two_CD related_VBN ERs_NNP (_( ERα_NNP and_CC ERβ_NNP )_)
        that_WDT conform_VBP to_TO the_DT typical_JJ three_CD domain_NN NR_NNP structure_NN and_CC
        share_VB extensive_JJ sequence_NN homology_NN in_IN the_DT DBD_NNP and_CC LBD_NNP region_NN
        [_NN 20_CD 21_CD ]_NN ._. Analysis_NNP of_IN the_DT function_NN of_IN the_DT individual_JJ ERs_NNP
        in_IN mouse_NN knockout_NN models_NNS suggests_VBZ that_IN the_DT major_JJ
        proliferative_JJ effects_NNS of_IN estrogen_NN are_VBP mediated_JJ by_IN ERα_NNP and_CC
        not_RB by_IN ERβ_NNP ,_, which_WDT seems_VBZ to_TO play_VB an_DT inhibitory_NN role_NN in_IN
        proliferation_NN in_IN some_DT studies_NNS [_NN 22_CD 23_CD ]_NN ._. The_DT
        ligand-binding_JJ properties_NNS of_IN the_DT ERs_NNP are_VBP different_JJ ,_, with_IN
        ERβ_NNP often_RB exhibiting_VBG stronger_JJR binding_JJ to_TO plant-derived_JJ
        phytoestrogens_NNS [_NN 24_CD ]_NN ._. More_RBR importantly_RB ,_, the_DT ERs_NNP exhibit_NN
        isoform-specific_JJ effects_NNS on_IN gene_NN expression_NN ._. Both_DT ERs_NNP
        enhance_VB transcription_NN from_IN genes_NNS with_IN classical_JJ estrogen_NN
        response_NN elements_NNS (_( EREs_NNP )_) ,_, but_CC ERα_NNP requires_VBZ less_JJR ligand_NN to_TO
        obtain_VB maximal_NN activation_NN than_IN ERβ_NNP [_NN 25_CD 26_CD ]_NN ._. Likewise_RB ,_,
        both_DT ERs_NNP suppress_VB the_DT activity_NN of_IN the_DT TNFα_NNP promoter_NN in_IN
        response_NN to_TO estrogens_NNS ,_, but_CC ERβ_NNP is_VBZ a_DT more_RBR potent_JJ repressor_NN
        than_IN ERα_NNP [_NN 27_CD ]_NN ._. However_RB ,_, some_DT of_IN the_DT most_RBS striking_JJ
        isoform-specific_JJ differences_NNS in_IN gene_NN regulation_NN are_VBP
        observed_VBN at_IN promoters_NNS ,_, such_JJ as_IN that_DT of_IN cyclin_NN D_NNP 1_CD ,_, which_WDT
        contain_VBP AP-_NNP 1_CD sites_NNS or_CC related_VBN cyclic_JJ AMP_NNP response_NN elements_NNS
        (_( CREs_NNP )_) ._. ERα_NNP enhances_VBZ AP-_NNP 1_CD activity_NN in_IN response_NN to_TO
        estrogens_NNS ,_, [_NN 28_CD 29_CD ]_NN but_CC ERβ_NNP inhibits_NNS AP-_NNP 1_CD activity_NN in_IN
        response_NN to_TO estrogens_NNS [_NN 29_CD 30_CD 31_CD ]_NN ._. ERβ_NNP also_RB completely_RB
        suppresses_NNS ERα_NNP activity_NN at_IN the_DT cyclin_NN D_NNP 1_CD promoter_NN and_CC even_RB
        suppresses_NNS the_DT activity_NN of_IN an_DT ERα_NNP mutant_JJ that_WDT is_VBZ
        selectively_RB superactive_JJ at_IN AP-_NNP 1_CD sites_NNS and_CC CREs_NNP [_NN 29_CD ]_NN ._.
        Finally_RB ,_, ERβ_NNP shows_VBZ a_DT unique_JJ capacity_NN to_TO enhance_VB AP-_NNP 1_CD
        activity_NN in_IN response_NN to_TO selective_JJ estrogen_NN receptor_NN
        modulators_NNS (_( SERMs_NNP )_) such_JJ as_IN raloxifene_NN ,_, tamoxifen_NN and_CC ICI_NNP
        182_CD ,_, 780_CD /_NN Faslodex_NNP (_( ICI_NNP )_) [_NN 30_CD 31_CD 32_CD ]_NN ._. Together_RB ,_, these_DT
        observations_NNS suggest_VBP that_IN there_EX are_VBP fundamental_JJ differences_NNS
        in_IN the_DT way_NN that_IN the_DT ERs_NNP bind_NN unspecified_JJ cofactors_NNS that_WDT
        modulate_VBP gene_NN expression_NN ,_, and_CC that_IN some_DT of_IN these_DT cofactors_NNS
        must_MD play_VB a_DT role_NN in_IN differential_NN ER_NNP activity_NN at_IN AP-_NNP 1_CD
        sites_NNS ._.
        Although_IN the_DT poorly_RB conserved_JJ NTD_NNP region_NN clearly_RB plays_VBZ
        an_DT important_JJ role_NN in_IN isoform-specificity_JJ [_NN 32_CD 33_CD ]_NN ,_, it_PRP is_VBZ
        also_RB likely_JJ that_IN there_EX are_VBP differences_NNS in_IN the_DT better_RBR
        conserved_JJ LBD_NNP region_NN that_WDT contribute_VBP to_TO differential_NN ERα_NNP
        and_CC ERβ_NNP activities_NNS ._. Phage_NNP display_NN techniques_NNS have_VBP revealed_VBN
        that_IN ERα_NNP and_CC ERβ_NNP show_NN different_JJ preferences_NNS in_IN LXXLL_NNP
        binding_JJ (_( reviewed_VBN in_IN [_NN 34_CD 35_CD ]_NN )_) ._. Moreover_RB ,_, some_DT cofactors_NNS
        that_WDT contain_VBP LXXLL_NNP motifs_NNS show_VBP differential_NN binding_JJ to_TO LBDs_NNP
        of_IN the_DT ER_NNP isoforms_NNS (_( reviewed_VBN in_IN [_NN 36_CD ]_NN )_) ._. SHP_NNP binds_NNS ERα_NNP
        preferentially_RB [_NN 37_CD ]_NN ,_, and_CC represses_NNS ERα_NNP activity_NN more_RBR
        strongly_RB than_IN that_DT of_IN ERβ_NNP ._. The_DT PGC-_NNP 1_CD related_VBN protein_NN PERC_NNP
        also_RB binds_NNS ERα_NNP preferentially_RB ,_, and_CC potentiates_NNS ERα_NNP activity_NN
        more_RBR strongly_RB than_IN that_DT of_IN ERβ_NNP [_NN 38_CD ]_NN ._. We_PRP recently_RB
        observed_VBD that_IN ERα_NNP binds_NNS the_DT C-_NNP terminal_NN NR_NNP interacting_VBG
        regions_NNS of_IN N-C_NNP oR_NN and_CC SMRT_NNP in_IN the_DT presence_NN of_IN SERMs_NNP but_CC not_RB
        estrogens_NNS [_NN 39_CD ]_NN ._. In_IN this_DT study_NN ,_, we_PRP report_VBP that_IN ERβ_NNP
        interactions_NNS with_IN N-C_NNP oR_NN and_CC SMRT_NNP are_VBP promoted_VBN by_IN agonists_NNS
        and_CC inhibited_VBD by_IN SERMs_NNP ._. Thus_RB ,_, the_DT ERs_NNP show_NN completely_RB
        opposite_JJ ligand_NN preferences_NNS of_IN interaction_NN with_IN
        corepressors_NNS ._. We_PRP discuss_VBP the_DT potential_JJ significance_NN of_IN
        these_DT different_JJ modes_NNS of_IN ER_NNP interaction_NN with_IN N-C_NNP oR_NN in_IN terms_NNS
        of_IN known_VBN isoform-specific_JJ behaviors_NNS ._.
      
      
        Results_NNS
        
          Agonist_NNP Dependent_NNP ERβ_NNP Interactions_NNP with_IN N-C_NNP oR_NN and_CC
          SMRT_NNP
          To_TO investigate_VB ERβ_NNP interactions_NNS with_IN corepressors_NNS ,_, we_PRP
          examined_VBD the_DT interactions_NNS of_IN full_JJ length_NN ERβ_NNP (_( amino_JJ acids_NNS
          1_CD -_: 530_CD )_) with_IN bacterially_RB expressed_VBD C-_NNP terminal_NN NR_NNP
          interacting_VBG domain_NN of_IN N-C_NNP oR_NN (_( amino_JJ acids_NNS 1944_CD -_: 2453_CD )_) 
          in_IN vitro_NN (_( Fig_NNP ._. 1_LS A_DT )_) ._. Fig_NNP ._. 1_LS Breveals_NNP ,_,
          surprisingly_RB ,_, that_IN ERβ_NNP bound_VBN N-C_NNP oR_NN in_IN the_DT absence_NN of_IN
          hormone_NN and_CC in_IN the_DT presence_NN of_IN agonist_NN ligands_NNS (_( E_NNP 2_CD ,_, DES_NNP )_)
          and_CC phytoestrogens_NNS (_( genistein_NN ,_, coumestrol_NN )_) ._. Moreover_RB ,_,
          these_DT interactions_NNS were_VBD suppressed_VBN by_IN SERMs_NNP (_( ICI_NNP ,_,
          raloxifene_NN and_CC tamoxifen_NN )_) ._. ERβ_NNP bound_VBN to_TO the_DT coactivator_NN
          GRIP_NNP 1_CD more_RBR strongly_RB than_IN N-C_NNP oR_NN ,_, but_CC did_VBD so_RB with_IN an_DT
          identical_JJ ligand_NN preference_NN ._. Similar_JJ agonist-dependent_JJ
          interactions_NNS could_MD be_VB observed_VBN between_IN ERβ_NNP and_CC the_DT
          alternate_JJ NR_NNP corepressor_NN SMRT_NNP 
          in_IN vitro_NN (_( Fig_NNP ._. 1_LS C_NNP )_) ._. Control_NNP binding_JJ
          experiments_NNS performed_VBN in_IN parallel_RB confirmed_VBD that_IN ERα_NNP
          bound_VBN to_TO N-C_NNP oR_NN in_IN the_DT presence_NN of_IN SERMs_NNP ,_, and_CC not_RB
          estradiol_NN (_( Fig_NNP ._. 1_LS D_NNP )_) and_CC that_IN TRβ_NNP bound_VBN N-C_NNP oR_NN in_IN the_DT
          absence_NN of_IN hormone_NN ,_, and_CC was_VBD released_VBN in_IN the_DT presence_NN of_IN
          T_NN 3_CD ,_, whereas_IN TRβ_NNP only_RB bound_VBN GRIP_NNP 1_CD in_IN the_DT presence_NN of_IN T_NN 3_CD
          (_( Fig_NNP ._. 1_LS E_NNP )_) ._.
          To_TO examine_VB interactions_NNS between_IN ERβ_NNP and_CC N-C_NNP oR_NN in_IN
          mammalian_JJ cells_NNS we_PRP performed_VBD two-hybrid_JJ assays_NNS using_VBG a_DT
          GAL_NNP 4_CD DBD_NNP /_NN N-C_NNP oR_NN C-_NNP terminus_JJ fusion_NN protein_NN as_IN bait_NN and_CC a_DT
          VP_NNP 16_CD -_: ERβ_NNP LBD_NNP fusion_NN as_IN the_DT prey_NN ._. Fig_NNP ._. 2_LS shows_VBZ that_IN the_DT
          ERβ-LBD_NNP bound_VBN N-C_NNP oR_NN in_IN the_DT presence_NN of_IN agonists_NNS and_CC
          phytoestrogens_NNS ,_, but_CC not_RB SERMs_NNP ._. Control_NNP two-hybrid_JJ assays_NNS
          confirmed_VBD that_IN a_DT VP_NNP 16_CD -_: TRβ_NNP LBD_NNP fusion_NN protein_NN bound_VBN N-C_NNP oR_NN
          in_IN the_DT absence_NN of_IN hormone_NN ,_, but_CC not_RB in_IN the_DT presence_NN of_IN T_NN 3_CD ._.
          E_NNP 2_CD dependent_JJ binding_JJ of_IN ERβ_NNP to_TO N-C_NNP oR_NN was_VBD dose_NN dependent_JJ
          (_( Fig_NNP ._. 2_LS B_NNP )_) with_IN an_DT EC_NNP 50_CD (_( 0_CD ._. 3_LS nM_NN )_) that_IN resembled_JJ that_IN of_IN
          ERβ_NNP binding_VBG to_TO the_DT GRIP_NNP 1_CD NR_NNP box_NN region_NN (_( amino_JJ acids_NNS
          610_CD -_: 770_CD )_) ._. Thus_RB ,_, ERβ_NNP binds_NNS the_DT N-C_NNP oR_NN C-_NNP terminal_NN NR_NNP
          interacting_VBG region_NN in_IN the_DT presence_NN of_IN agonists_NNS ,_, but_CC not_RB
          SERMs_NNP ,_, and_CC does_VBZ so_RB 
          in_IN vitro_NN and_CC in_IN mammalian_JJ cells_NNS ._.
          Moreover_RB ,_, results_NNS from_IN the_DT two-hybrid_JJ assay_NN indicate_VBP that_IN
          the_DT ERβ_NNP LBD_NNP is_VBZ sufficient_JJ to_TO obtain_VB estrogen-dependent_JJ
          interactions_NNS with_IN N-C_NNP oR_NN ._.
        
        
          ERβ_NNP Interactions_NNP with_IN N-C_NNP oR_NN are_VBP Dependent_NNP on_IN AF-_NNP 2_CD
          and_CC require_VB H_NNP 12_CD
          Unliganded_NNP NRs_NNP usually_RB bind_NN ID_NNP motifs_NNS (_( consensus_NN
          L_NNP /_NN IXXIIXXXL_NNP )_) in_IN the_DT N-C_NNP oR_NN C-_NNP terminus_JJ ._. To_TO ask_VB whether_IN ERβ_NNP
          might_MD bind_NN these_DT motifs_NNS in_IN the_DT presence_NN of_IN estradiol_NN ,_, we_PRP
          examined_VBD the_DT ability_NN of_IN peptides_NNS containing_VBG known_VBN NR_NNP
          interacting_VBG motifs_NNS to_TO compete_VB for_IN the_DT interaction_NN (_( Fig_NNP ._.
          3_LS A_DT )_) ._. A_DT peptide_NN overlapping_VBG to_TO the_DT N-C_NNP oR_NN ID_NNP 1_CD motif_NN (_( amino_JJ
          acids_NNS 2265_CD -_: 2291_CD )_) that_WDT competes_VBZ for_IN N-C_NNP oR_NN binding_JJ to_TO
          unliganded_JJ TR_NNP and_CC RAR_NNP [_NN 16_CD ]_NN failed_VBD to_TO compete_VB for_IN
          agonist-dependent_JJ ERβ_NNP interactions_NNS with_IN N-C_NNP oR_NN ._. By_IN
          contrast_NN ,_, a_DT peptide_NN corresponding_JJ to_TO GRIP_NNP 1_CD NR_NNP box_NN 2_CD did_VBD
          compete_VB for_IN this_DT interaction_NN [_NN 40_CD 41_CD ]_NN ._. This_DT finding_VBG
          suggests_VBZ that_IN agonist-bound_JJ ERβ_NNP does_VBZ not_RB recognize_VB ID_NNP
          motifs_NNS ,_, and_CC that_IN ERβ_NNP interactions_NNS with_IN N-C_NNP oR_NN more_RBR closely_RB
          resemble_VB those_DT with_IN GRIP_NNP 1_CD ._.
          NR_NNP interactions_NNS with_IN N-C_NNP oR_NN are_VBP usually_RB mediated_JJ by_IN a_DT
          hydrophobic_JJ cleft_NN that_IN spans_NNS residues_NNS from_IN H_NNP 3_CD and_CC H_NNP 5_CD and_CC
          includes_VBZ residues_NNS that_WDT lie_VBP under_IN H_NNP 12_CD in_IN the_DT liganded_JJ
          configuration_NN [_NN 4_CD 17_CD ]_NN ._. These_DT interactions_NNS are_VBP either_CC
          independent_JJ of_IN ,_, or_CC inhibited_VBD by_IN ,_, NR_NNP H_NNP 12_CD [_NN 17_CD 39_CD 42_CD ]_NN ._. By_IN
          contrast_NN ,_, NR_NNP interactions_NNS with_IN coactivators_NNS are_VBP mediated_JJ
          by_IN residues_NNS from_IN the_DT upper_JJ part_NN of_IN H_NNP 3_CD -_: H_NNP 5_CD and_CC also_RB require_VB
          H_NNP 12_CD itself_PRP [_NN 18_CD ]_NN ._. Fig_NNP ._. 3_LS Bshows_NNP that_IN a_DT mutation_NN in_IN a_DT
          conserved_JJ residue_NN on_IN H_NNP 12_CD that_WDT is_VBZ required_VBN for_IN coactivator_NN
          binding_JJ (_( E_NNP 493_CD K_NNP )_) abolished_VBD the_DT interaction_NN of_IN ERβ_NNP with_IN
          both_DT N-C_NNP oR_NN and_CC GRIP_NNP 1_CD ._. Moreover_RB ,_, other_JJ mutations_NNS in_IN the_DT
          upper_JJ part_NN of_IN the_DT H_NNP 3_CD -_: H_NNP 5_CD region_NN that_WDT comprises_VBZ the_DT AF-_NNP 2_CD
          surface_NN (_( D_NNP 303_CD Y_NNP ,_, I_PRP 310_CD R_NN and_CC K_NNP 314_CD A_DT on_IN H_NNP 3_CD ;_: V_NNP 328_CD R_NN and_CC L_NNP 331_CD R_NN on_IN
          H_NNP 5_LS )_) abolished_VBN ERβ_NNP interaction_NN with_IN both_DT cofactors_NNS ._.
          Control_NN mutations_NNS in_IN other_JJ regions_NNS of_IN the_DT ERβ_NNP surface_NN
          left_VBD its_PRP$ interactions_NNS with_IN N-C_NNP oR_NN and_CC GRIP_NNP 1_CD either_CC
          slightly_RB reduced_VBN or_CC intact_JJ (_( these_DT are_VBP L_NNP 301_CD R_NN at_IN the_DT base_NN
          of_IN H_NNP 3_CD ,_, V_NNP 361_CD R_NN in_IN the_DT S-_NNP bends_NNS ,_, M_NNP 379_CD R_NN in_IN H_NNP 8_CD ;_: L_NNP 426_CD R_NN ,_, T_NN 434_CD R_NN in_IN
          the_DT H_NNP 10_CD and_CC Y_NNP 488_CD S_NNP in_IN the_DT H_NNP 11_CD -_: H_NNP 12_CD loop_NN )_) ._. Thus_RB ,_, ERβ_NNP
          interactions_NNS with_IN N-C_NNP oR_NN are_VBP dependent_JJ on_IN the_DT AF-_NNP 2_CD surface_NN
          (_( including_VBG H_NNP 12_CD )_) and_CC ,_, in_IN this_DT regard_NN ,_, resemble_VBP those_DT of_IN
          ERβ_NNP and_CC GRIP_NNP 1_CD ._.
        
        
          ERβ_NNP Binds_NNP an_DT NR_NNP Box-_NNP Like_IN Motif_NN in_IN the_DT N-C_NNP oR_NN
          C-_NNP terminus_JJ
          To_TO map_VB the_DT region_NN of_IN N-C_NNP oR_NN that_IN interacted_JJ with_IN ERβ_NNP ,_,
          we_PRP examined_VBD ERβ_NNP binding_VBG to_TO a_DT series_NN of_IN rationally_RB
          designed_VBN smaller_JJR fragments_NNS of_IN the_DT N-C_NNP oR_NN C-_NNP terminus_JJ (_( Fig_NNP ._.
          4_LS )_) ._. ERβ_NNP did_VBD not_RB bind_NN two_CD of_IN these_DT smaller_JJR fragments_NNS of_IN
          N-C_NNP oR_NN (_( 1944_CD -_: 2033_CD ;_: 2230_CD -_: 2322_CD )_) that_WDT contain_VBP known_VBN ID_NNP motifs_NNS
          (_( IDs_NNP 3_CD and_CC 1_CD [_NN 16_CD ]_NN )_) ._. ERβ_NNP bound_VBN weakly_RB to_TO two_CD regions_NNS of_IN
          N-C_NNP oR_NN (_( 2033_CD -_: 2123_CD ;_: 2123_CD -_: 2230_CD )_) ,_, one_CD of_IN which_WDT (_( 2033_CD -_: 2123_CD )_)
          contains_VBZ an_DT ID_NNP motif_NN (_( ID_NNP 2_LS )_) ,_, but_CC did_VBD so_RB in_IN a_DT
          ligand-independent_JJ fashion_NN ._. However_RB ,_, ERβ_NNP did_VBD bind_NN to_TO a_DT
          fragment_NN that_WDT spanned_VBD the_DT extreme_JJ C-_NNP terminus_JJ (_( 2322_CD -_: 2453_CD )_)
          and_CC did_VBD so_RB in_IN a_DT manner_NN that_WDT was_VBD promoted_VBN by_IN E_NNP 2_CD and_CC
          suppressed_VBN by_IN ICI_NNP ,_, much_JJ like_IN the_DT interactions_NNS of_IN ERβ_NNP with_IN
          the_DT entire_JJ N-C_NNP oR_NN nuclear_JJ receptor_NN interacting_VBG region_NN ._.
          The_DT interaction_NN of_IN ERβ_NNP with_IN the_DT small_JJ N-C_NNP oR_NN C-_NNP terminal_NN
          fragment_NN (_( amino_JJ acids_NNS 2322_CD -_: 2453_CD )_) was_VBD stronger_JJR than_IN that_DT
          observed_VBD with_IN the_DT intact_JJ C-_NNP terminus_JJ (_( amino_JJ acids_NNS
          1944_CD -_: 2453_CD )_) ._. This_DT apparently_RB improved_VBN binding_JJ is_VBZ likely_JJ to_TO
          be_VB a_DT consequence_NN of_IN our_PRP$ methodology_NN (_( West_NNP 
          et_CC al_NN ._. Unpublished_NNP data_NNS )_) ._. In_IN
          general_JJ ,_, expression_NN of_IN large_JJ fragments_NNS of_IN the_DT N-C_NNP oR_NN
          C-_NNP terminus_JJ in_IN E_NNP ._. Coli_NNP yields_VBZ a_DT mix_NN of_IN full_JJ length_NN protein_NN
          along_IN with_IN truncated_JJ products_NNS ._. To_TO create_VB the_DT expression_NN
          vectors_NNS for_IN the_DT smaller_JJR fragments_NNS ,_, truncated_JJ N-C_NNP oR_NN
          polypeptides_NNS that_WDT were_VBD obtained_VBN in_IN E_NNP ._. Coli_NNP extracts_NNS were_VBD
          subjected_VBN to_TO protein_NN sequence_NN analysis_NN and_CC cDNA_NN fragments_NNS
          that_WDT coded_VBN for_IN the_DT major_JJ truncated_JJ products_NNS were_VBD
          prepared_VBN ._. Each_DT of_IN the_DT resulting_VBG polypeptides_NNS was_VBD
          expressed_VBN very_RB efficiently_RB in_IN E_NNP ._. Coli_NNP ._. The_DT end_NN product_NN
          that_WDT was_VBD obtained_VBN after_IN GST_NNP purification_NN essentially_RB
          consisted_VBD of_IN a_DT single_JJ short_JJ polypeptide_NN as_IN judged_VBN by_IN
          Coomassie_NNP stain_VB ._. Binding_NNP of_IN ERβ_NNP to_TO N-C_NNP oR_NN (_( 2322_CD -_: 2453_CD )_) is_VBZ
          probably_RB very_RB efficient_JJ for_IN two_CD reasons_NNS ._. First_LS ,_, equal_JJ
          amounts_NNS of_IN GST_NNP fusion_NN protein_NN were_VBD used_VBN as_IN baits_NNS for_IN the_DT
          translated_VBN ERβ_NNP protein_NN in_IN this_DT series_NN of_IN experiments_NNS (_( 3_CD μg_NN
          per_IN assay_NN )_) ._. Thus_RB ,_, N-C_NNP oR_NN (_( 2322_CD -_: 2453_CD )_) is_VBZ present_JJ in_IN molar_NN
          excess_JJ over_IN N-C_NNP oR_NN (_( 1944_CD -_: 2453_CD )_) ._. Second_JJ ,_, as_IN developed_VBN
          above_IN ,_, preparations_NNS of_IN N-C_NNP oR_NN (_( 1944_CD -_: 2453_CD )_) generally_RB
          contain_VB truncated_JJ products_NNS ,_, so_RB sequences_NNS corresponding_JJ to_TO
          the_DT extreme_JJ N-C_NNP oR_NN C-_NNP terminus_JJ (_( which_WDT binds_NNS ERβ_NNP )_) is_VBZ
          markedly_RB under-represented_JJ ._. In_IN any_DT case_NN ,_, the_DT fact_NN that_IN
          ERβ_NNP binds_NNS weakly_RB or_CC not_RB at_IN all_DT to_TO the_DT three_CD N-C_NNP oR_NN ID_NNP
          motifs_NNS that_WDT mediate_VB interactions_NNS with_IN TRs_NNP and_CC RARs_NNP and_CC ,_,
          instead_RB ,_, binds_NNS in_IN an_DT agonist-dependent_JJ fashion_NN to_TO a_DT
          region_NN in_IN the_DT C-_NNP terminus_JJ of_IN N-C_NNP oR_NN that_WDT has_VBZ not_RB previously_RB
          been_VBN implicated_VBN in_IN NR_NNP interactions_NNS indicates_VBZ that_IN ERβ_NNP
          recognizes_VBZ a_DT novel_NN protein_NN sequence_NN motif_NN within_IN
          N-C_NNP oR_NN ._.
          The_DT N-C_NNP oR_NN C-_NNP terminus_JJ contains_VBZ the_DT sequence_NN PLTIRMLS_NNP
          (_( β-box_JJ ,_, amino_JJ acids_NNS 2399_CD -_: 2406_CD ;_: Fig_NNP ._. 5_LS )_) ._. This_DT sequence_NN
          does_VBZ not_RB exactly_RB conform_VB to_TO the_DT LXXLL_NNP consensus_NN ,_, but_CC
          contains_VBZ features_NNS (_( underlined_VBD )_) that_WDT resemble_VBP the_DT ERβ_NNP H_NNP 12_CD
          region_NN (_( L_NNP 
          L_NNP LE_NNP 
          ML_NNP )_) ,_, and_CC artificial_JJ ERβ_NNP
          interacting_VBG LXXLL_NNP peptides_NNS (_( 293_CD ,_, 
          P_NN NLIS_NNP 
          LLS_NNP ;_: D_NNP 47_CD ,_, 
          PL_NNP LLS_NNP 
          LLS_NNP )_) ,_, both_DT of_IN which_WDT bind_NN to_TO the_DT
          ERβ_NNP AF-_NNP 2_CD surface_NN [_NN 43_CD 44_CD 45_CD 46_CD 47_CD ]_NN ._. Moreover_RB ,_, the_DT
          presence_NN of_IN a_DT proline_NN residue_NN amino-terminal_JJ to_TO the_DT
          hydrophobic_JJ groups_NNS is_VBZ typical_JJ of_IN so-called_JJ class_NN II_NNP LXXLL_NNP
          motifs_NNS which_WDT are_VBP found_VBN in_IN ERβ_NNP interacting_VBG cofactors_NNS such_JJ
          as_IN TRAP_NNP 220_CD and_CC RIP_NNP 140_CD [_NN 45_CD ]_NN ._. Finally_RB ,_, the_DT unusual_JJ
          C-_NNP terminal_NN hydrophobic_JJ pair_NN (_( ML_NNP )_) has_VBZ been_VBN observed_VBN in_IN ERα_NNP
          and_CC ERβ_NNP H_NNP 12_CD [_NN 43_CD 44_CD 48_CD ]_NN ,_, and_CC in_IN RIP_NNP 140_CD NR_NNP boxes_NNS [_NN 19_CD ]_NN
          ._.
          We_PRP investigated_VBD the_DT significance_NN of_IN the_DT β-box_JJ in_IN ERβ_NNP
          interactions_NNS with_IN N-C_NNP oR_NN ._. As_IN Fig_NNP ._. 6_CD Ashows_NNP ,_, a_DT synthetic_JJ
          β-box_JJ peptide_NN competed_VBN for_IN binding_JJ to_TO N-C_NNP oR_NN ,_, albeit_IN
          somewhat_RB less_RBR efficiently_RB than_IN native_JJ GRIP_NNP 1_CD NR_NNP box_NN 2_CD ._.
          Similar_JJ results_NNS were_VBD obtained_VBN in_IN competition_NN experiments_NNS
          that_WDT used_VBD GST-GRIP_NNP 1_CD instead_RB of_IN GST-N-CoR_NNP (_( data_NNS not_RB
          shown_VBN )_) ._. The_DT isolated_VBN β-box_JJ also_RB acted_VBD as_IN bait_NN for_IN a_DT
          VP_NNP 16_CD -_: ERβ_NNP fusion_NN protein_NN in_IN mammalian_JJ cells_NNS ,_, and_CC did_VBD so_RB
          with_IN similar_JJ efficiency_NN to_TO other_JJ known_VBN ERβ_NNP interacting_VBG
          peptides_NNS (_( Fig_NNP ._. 6_CD B_NNP )_) ._. Finally_RB ,_, mutations_NNS within_IN the_DT β-box_JJ
          (_( especially_RB M_NNP 2405_CD A_DT ,_, L_NNP 2406_CD A_DT )_) disrupted_VBN ERβ_NNP interactions_NNS
          with_IN N-C_NNP oR_NN in_IN mammalian_JJ two-hybrid_JJ assays_NNS ,_, but_CC did_VBD not_RB
          affect_VB TRβ_NNP interactions_NNS (_( Fig_NNP ._. 6_CD C_NNP )_) ._. Thus_RB ,_, the_DT β-box_JJ is_VBZ
          sufficient_JJ to_TO bind_NN ERβ_NNP and_CC is_VBZ essential_JJ for_IN
          agonist-dependent_JJ ERβ_NNP interactions_NNS with_IN the_DT N-C_NNP oR_NN
          C-_NNP terminus_JJ ._.
          Next_JJ ,_, we_PRP examined_VBD whether_IN the_DT β-box_JJ would_MD bind_NN other_JJ
          NRs_NNP ._. The_DT Gal-β-box_NNP fusion_NN failed_VBD to_TO recruit_VB the_DT ERα_NNP ,_, TRβ_NNP
          or_CC RARβ_NNP LBDs_NNP in_IN mammalian_JJ two-hybrid_JJ assays_NNS (_( Fig_NNP ._. 7_CD A_DT )_) ._.
          Moreover_RB ,_, while_IN the_DT β-box_JJ and_CC GRIP_NNP 1_CD NR_NNP box_NN 2_CD peptides_NNS
          both_DT competed_VBN for_IN ERβ_NNP interactions_NNS with_IN GRIP_NNP 1_CD ,_, only_RB the_DT
          NR_NNP box_NN 2_CD peptide_NN competed_VBN for_IN ERα_NNP interactions_NNS with_IN GRIP_NNP 1_CD
          (_( Fig_NNP ._. 7_CD B_NNP )_) ._. Thus_RB ,_, the_DT N-C_NNP oR_NN β-box_JJ is_VBZ ,_, at_IN least_JJS to_TO some_DT
          degree_NN ,_, ERβ_NNP specific_NN ._. Mutation_NNP of_IN N-C_NNP oR_NN to_TO obtain_VB a_DT β-box_JJ
          sequence_NN that_IN more_JJR closely_RB resembled_JJ a_DT conventional_JJ LXXLL_NNP
          motif_NN (_( T_NN 2402_CD L_NNP )_) led_VBN to_TO enhanced_VBN hormone-dependent_JJ
          interactions_NNS with_IN ERβ_NNP and_CC permitted_VBN novel_NN
          hormone-dependent_JJ interactions_NNS with_IN ERα_NNP (_( Fig_NNP ._. 7_CD C_NNP )_) ._. Thus_RB ,_,
          some_DT of_IN the_DT observed_VBN ERβ_NNP specificity_NN is_VBZ probably_RB a_DT
          consequence_NN of_IN an_DT unexpected_JJ ability_NN to_TO tolerate_VB the_DT
          absence_NN of_IN a_DT leucine_NN residue_NN at_IN the_DT N-_NNP terminus_JJ of_IN the_DT
          LXXLL_NNP motif_NN ._. Together_RB ,_, our_PRP$ results_NNS indicate_VBP that_IN ERβ_NNP has_VBZ
          the_DT potential_NN to_TO utilize_VB its_PRP$ AF-_NNP 2_CD surface_NN to_TO bind_NN NR_NNP
          boxes_NNS within_IN coactivators_NNS or_CC an_DT NR_NNP box-like_JJ sequence_NN in_IN
          the_DT C-_NNP terminus_JJ of_IN N-C_NNP oR_NN ._.
        
        
          A_DT HDAC_NNP Repressor_NNP Enhances_NNP ERβ_NNP Activity_NN
          Since_IN ERβ_NNP bound_VBN N-C_NNP oR_NN and_CC SMRT_NNP in_IN the_DT presence_NN of_IN
          estrogens_NNS ,_, we_PRP investigated_VBD the_DT possible_JJ involvement_NN of_IN
          corepressors_NNS in_IN the_DT actions_NNS of_IN agonist-bound_JJ ERβ_NNP 
          in_IN vivo_NN ._. To_TO perform_VB this_DT
          experiment_NN ,_, we_PRP examined_VBD the_DT effect_NN of_IN the_DT HDAC_NNP inhibitor_NN
          trichostatin_NN A_DT (_( TSA_NNP )_) on_IN ERβ_NNP activity_NN in_IN transiently_RB
          transfected_JJ HeLa_NNP cells_NNS ._. Fig_NNP ._. 8_CD Aconfirms_NNP that_IN ERα_NNP shows_VBZ
          stronger_JJR transcriptional_NN activity_NN than_IN ERβ_NNP at_IN a_DT simple_JJ
          ERE_NNP responsive_JJ reporter_NN gene_NN ._. TSA_NNP enhanced_VBD the_DT basal_NN
          activity_NN of_IN the_DT ERE-TK_NNP reporter_NN gene_NN by_IN about_IN
          fifteen-fold_JJ in_IN the_DT absence_NN of_IN ER_NNP (_( see_VB inset_NN )_) ._. However_RB ,_,
          TSA_NNP also_RB equalized_JJ the_DT relative_JJ transcriptional_NN activity_NN
          of_IN both_DT ERs_NNP ._. Fig_NNP ._. 8_CD Bshows_NNP that_IN the_DT isolated_VBN ERα_NNP LBD_NNP
          exhibited_VBN more_RBR potent_JJ transcriptional_NN activity_NN than_IN the_DT
          ERβ_NNP LBD_NNP ._. However_RB ,_, both_DT LBDs_NNP showed_VBD similar_JJ
          transcriptional_NN activity_NN in_IN the_DT presence_NN of_IN TSA_NNP ._. Thus_RB ,_,
          corepressor_NN complex_JJ HDACs_NNP must_MD play_VB an_DT unspecified_JJ role_NN
          in_IN restricting_VBG the_DT transcriptional_NN activity_NN of_IN both_DT ERβ_NNP
          and_CC ,_, in_IN particular_JJ ,_, the_DT ERβ-LBD_NNP ._. This_DT is_VBZ consistent_JJ with_IN
          the_DT notion_NN that_IN corepressors_NNS restrict_VBP the_DT activity_NN of_IN
          agonist-bound_JJ ERβ-LBD_NNP ._.
        
      
      
        Conclusions_NNP
        NRs_NNP generally_RB interact_NN with_IN the_DT corepressors_NNS N-C_NNP oR_NN and_CC
        SMRT_NNP either_CC in_IN the_DT absence_NN of_IN ligand_NN ,_, or_CC in_IN the_DT presence_NN of_IN
        receptor_NN antagonists_NNS ,_, and_CC agonists_NNS promote_VBP corepressor_NN
        release_NN [_NN 4_CD ]_NN ._. In_IN this_DT study_NN ,_, we_PRP demonstrated_VBD that_IN ERβ_NNP
        binds_NNS to_TO N-C_NNP oR_NN in_IN the_DT presence_NN of_IN ER_NNP agonists_NNS such_JJ as_IN
        estradiol_NN and_CC DES_NNP and_CC the_DT phytoestrogens_NNS genistein_NN and_CC
        coumestrol_NN ,_, but_CC not_RB in_IN the_DT presence_NN of_IN SERMs_NNP ._. Moreover_RB ,_,
        this_DT interaction_NN is_VBZ dependent_JJ upon_IN ERβ_NNP AF-_NNP 2_CD ,_, including_VBG H_NNP 12_CD ,_,
        and_CC is_VBZ competed_VBN by_IN NR_NNP box_NN peptides_NNS but_CC not_RB ID_NNP peptides_NNS ._. The_DT
        hormone-dependent_JJ component_NN of_IN the_DT ERβ_NNP /_NN N-C_NNP oR_NN interaction_NN
        maps_NNS to_TO the_DT extreme_JJ C-_NNP terminus_JJ of_IN N-C_NNP oR_NN ,_, which_WDT has_VBZ not_RB been_VBN
        previously_RB implicated_VBN in_IN NR_NNP interactions_NNS ,_, and_CC requires_VBZ a_DT
        sequence_NN that_WDT resembles_VBZ an_DT ERβ-specific_NNP NR_NNP box_NN (_( PLTIRMLS_NNP ,_,
        β-box_JJ )_) ._. In_IN this_DT regard_NN ,_, ERβ_NNP differs_VBZ from_IN ERα_NNP ,_, which_WDT
        probably_RB binds_NNS ID_NNP motifs_NNS in_IN a_DT SERM-dependent_NNP fashion_NN [_NN 49_CD
        50_CD ]_NN and_CC shows_VBZ reduced_VBN binding_JJ to_TO N-C_NNP oR_NN in_IN the_DT presence_NN of_IN
        estradiol_NN [_NN 39_CD ]_NN ._. ERβ_NNP also_RB differs_VBZ from_IN many_JJ other_JJ NRs_NNP ,_,
        which_WDT either_CC bind_NN N-C_NNP oR_NN in_IN the_DT absence_NN of_IN ligand_NN and_CC are_VBP
        released_VBN in_IN the_DT presence_NN of_IN ligand_NN or_CC interact_NN with_IN N-C_NNP oR_NN
        in_IN the_DT presence_NN of_IN antagonists_NNS but_CC not_RB agonists_NNS [_NN 4_CD ]_NN ._.
        The_DT fact_NN that_IN the_DT mode_NN of_IN ERβ_NNP interaction_NN with_IN N-C_NNP oR_NN
        resembles_VBZ that_IN of_IN NRs_NNP with_IN coactivators_NNS [_NN 4_CD ]_NN ,_, or_CC with_IN
        corepressors_NNS that_WDT modulate_VBP the_DT activity_NN of_IN liganded_JJ NR_NNP
        complexes_NNS ,_, such_JJ as_IN RIP_NNP 140_CD [_NN 10_CD ]_NN ,_, raises_VBZ the_DT possibility_NN
        that_IN ERβ_NNP may_MD be_VB able_JJ to_TO recruit_VB N-C_NNP oR_NN and_CC SMRT_NNP to_TO
        estrogen-regulated_JJ promoters_NNS in_IN response_NN to_TO agonists_NNS and_CC
        that_IN the_DT balance_NN of_IN overall_JJ ERβ_NNP activity_NN in_IN the_DT presence_NN of_IN
        estrogens_NNS may_MD be_VB regulated_VBN by_IN competition_NN between_IN p_NN 160_CD s_VBZ and_CC
        corepressors_NNS for_IN the_DT same_JJ ERβ_NNP AF-_NNP 2_CD surface_NN ._. We_PRP recognize_VBP
        that_IN our_PRP$ studies_NNS do_VBP not_RB directly_RB address_VB this_DT issue_NN ._. Our_PRP$
        attempts_NNS to_TO identify_VB ERβ_NNP mutants_NNS that_WDT differentiate_VB between_IN
        GRIP_NNP 1_CD and_CC N-C_NNP oR_NN binding_JJ to_TO analyze_VB the_DT role_NN of_IN
        agonist-dependent_JJ corepressor_NN binding_JJ have_VBP not_RB yet_RB been_VBN
        successful_JJ (_( probably_RB because_IN ERβ_NNP utilizes_NNS the_DT same_JJ surface_NN
        to_TO bind_NN both_DT cofactors_NNS )_) ._. Moreover_RB ,_, transfection_NN of_IN N-C_NNP oR_NN or_CC
        various_JJ mutated_VBN N-C_NNP oR_NN derivatives_NNS did_VBD not_RB significantly_RB
        affect_VB ERβ_NNP activity_NN at_IN EREs_NNP or_CC AP-_NNP 1_CD sites_NNS (_( data_NNS not_RB shown_VBN )_) ._.
        We_PRP do_VBP not_RB understand_VB why_WRB ,_, but_CC in_IN our_PRP$ hands_NNS ,_, transfected_JJ
        N-C_NNP oR_NN also_RB fails_VBZ to_TO affect_VB TR_NNP or_CC ERα_NNP activity_NN (_( data_NNS not_RB
        shown_VBN )_) ,_, despite_IN the_DT fact_NN that_IN it_PRP clearly_RB interacts_NNS with_IN
        both_DT NRs_NNP ._. Nevertheless_RB ,_, we_PRP suspect_VBP that_IN estrogen-dependent_JJ
        N-C_NNP oR_NN binding_JJ may_MD represent_VB an_DT important_JJ component_NN of_IN the_DT
        regulation_NN of_IN ERβ_NNP activity_NN ._. As_IN described_VBD in_IN the_DT
        Introduction_NNP ,_, ERα_NNP and_CC ERβ_NNP must_MD interact_NN differentially_RB with_IN
        factors_NNS that_WDT modulate_VBP ER_NNP activity_NN in_IN the_DT presence_NN of_IN
        estrogens_NNS ._. The_DT finding_VBG that_IN estrogens_NNS suppress_VB N-C_NNP oR_NN
        binding_JJ to_TO ERα_NNP [_NN 39_CD ]_NN ,_, but_CC promote_VB N-C_NNP oR_NN binding_JJ to_TO ERβ_NNP
        represents_VBZ the_DT first_JJ demonstration_NN of_IN a_DT corepressor_NN that_WDT
        shows_VBZ completely_RB distinct_JJ modes_NNS of_IN hormone-dependent_JJ
        interaction_NN with_IN the_DT ER_NNP isoforms_NNS ._. Thus_RB ,_, N-C_NNP oR_NN and_CC SMRT_NNP and_CC
        their_PRP$ associated_VBN HDACs_NNP are_VBP excellent_JJ candidates_NNS to_TO explain_VB
        some_DT of_IN the_DT differential_NN behaviors_NNS of_IN the_DT ER_NNP isoforms_NNS ._.
        Consistent_NNP with_IN this_DT notion_NN ,_, the_DT apparent_JJ weak_JJ
        transcriptional_NN activity_NN of_IN the_DT ERβ_NNP LBD_NNP is_VBZ a_DT consequence_NN of_IN
        corepressor_NN HDAC_NNP activity_NN at_IN some_DT level_NN (_( Fig_NNP ._. 8_CD )_) ._. Full_NNP
        verification_NN of_IN the_DT importance_NN of_IN ERβ_NNP interaction_NN with_IN
        N-C_NNP oR_NN will_MD await_VB demonstration_NN that_IN ERβ_NNP recruits_VBZ N-C_NNP oR_NN and_CC
        SMRT_NNP to_TO estrogen-regulated_JJ promoters_NNS 
        in_IN vivo_NN ,_, and_CC that_IN this_DT event_NN is_VBZ
        related_VBN to_TO modulation_NN of_IN estrogen_NN response_NN ._.
        While_IN the_DT ER_NNP isoforms_NNS have_VBP contrasting_VBG effects_NNS on_IN AP-_NNP 1_CD
        activity_NN in_IN the_DT presence_NN of_IN estrogens_NNS ,_, ERα_NNP truncations_NNS that_WDT
        lack_NN the_DT NTD_NNP and_CC ERβ_NNP both_DT enhance_VB AP-_NNP 1_CD activity_NN in_IN the_DT
        presence_NN of_IN SERMs_NNP [_NN 30_CD 31_CD ]_NN ._. Mutational_NNP analysis_NN of_IN ERα_NNP
        action_NN at_IN AP-_NNP 1_CD sites_NNS suggests_VBZ these_DT effects_NNS may_MD be_VB related_VBN
        to_TO N-C_NNP oR_NN binding_JJ [_NN 39_CD ]_NN ,_, and_CC we_PRP have_VBP proposed_VBN that_IN SERM_NNP
        action_NN at_IN AP-_NNP 1_CD sites_NNS may_MD therefore_RB involve_VB contacts_NNS with_IN
        corepressors_NNS [_NN 31_CD 51_CD ]_NN ._. The_DT fact_NN that_IN ERα_NNP and_CC ERβ_NNP show_NN
        completely_RB different_JJ ligand_NN preferences_NNS of_IN interaction_NN with_IN
        N-C_NNP oR_NN suggests_VBZ that_IN the_DT target_NN for_IN SERM_NNP activation_NN at_IN AP-_NNP 1_CD
        sites_NNS may_MD not_RB be_VB N-C_NNP oR_NN in_IN both_DT cases_NNS ._. Thus_RB ,_, this_DT finding_VBG
        complicates_VBZ our_PRP$ attempts_NNS to_TO explain_VB this_DT unusual_JJ
        phenomenon_NN ._. Perhaps_RB the_DT ER_NNP isoforms_NNS enhance_VB AP-_NNP 1_CD activity_NN
        by_IN superficially_RB similar_JJ mechanisms_NNS that_WDT involve_VBP different_JJ
        cofactors_NNS ._. Alternatively_RB ,_, ERα_NNP and_CC ERβ_NNP action_NN at_IN AP-_NNP 1_CD sites_NNS
        could_MD ,_, in_IN fact_NN ,_, be_VB mediated_JJ by_IN SERM-dependent_NNP contacts_NNS with_IN
        a_DT common_JJ cofactor_NN that_WDT is_VBZ ,_, as_IN yet_RB ,_, unidentified_JJ ._. This_DT
        common_JJ factor_NN may_MD yet_RB prove_VB to_TO be_VB N-C_NNP oR_NN if_IN ERβ_NNP interactions_NNS
        with_IN the_DT β-box_JJ were_VBD somehow_RB masked_VBN 
        in_IN vivo_NN ._.
        What_WP features_NNS of_IN the_DT β-box_JJ contribute_VB to_TO ERβ_NNP
        specificity_NN ?_. Intriguingly_NNP ,_, the_DT β-box_JJ contains_VBZ N-_NNP terminal_NN
        proline_NN and_CC C-_NNP terminal_NN serine_NN residues_NNS that_WDT extend_VBP the_DT
        homology_NN of_IN this_DT region_NN to_TO an_DT artificial_JJ ERβ-specific_NNP
        peptide_NN [_NN 45_CD ]_NN ._. However_RB ,_, the_DT β-box_JJ also_RB lacks_VBZ the_DT first_JJ
        Leu_NNP of_IN the_DT consensus_NN LXXLL_NNP ._. A_DT mutation_NN (_( PL_NNP 
        T_NN IRML_NNP >_NN PL_NNP 
        L_NNP IRML_NNP )_) that_IN restores_NNS the_DT LXXLL_NNP
        consensus_NN increases_NNS ERβ_NNP binding_JJ to_TO N-C_NNP oR_NN and_CC permits_VBZ ERα_NNP to_TO
        bind_NN to_TO N-C_NNP oR_NN in_IN the_DT presence_NN of_IN estrogens_NNS in_IN mammalian_JJ
        two-hybrid_JJ assays_NNS ._. Thus_RB ,_, the_DT unusual_JJ sequence_NN of_IN the_DT β-box_JJ
        contributes_VBZ to_TO ERβ_NNP specificity_NN and_CC ERβ_NNP can_MD tolerate_VB the_DT
        absence_NN of_IN a_DT conserved_JJ N-_NNP terminal_NN leucine_NN in_IN LXXLL_NNP motifs_NNS ._.
        ERβ_NNP might_MD bind_NN to_TO yet_RB more_JJR cofactors_NNS that_WDT contain_VBP variant_NN
        NR_NNP boxes_NNS that_WDT resemble_VBP the_DT β-box_JJ ._. Other_JJ aspects_NNS of_IN ERβ_NNP
        interactions_NNS with_IN corepressors_NNS warrant_VBP further_JJ study_NN ._. It_PRP
        will_MD be_VB interesting_JJ to_TO understand_VB whether_IN the_DT weaker_JJR ERβ_NNP
        interactions_NNS with_IN other_JJ regions_NNS of_IN N-C_NNP oR_NN (_( which_WDT are_VBP
        insensitive_JJ to_TO ICI_NNP )_) play_VB a_DT role_NN in_IN ERβ_NNP binding_JJ (_( Fig_NNP ._. 4_LS )_) ._.
        Finally_RB ,_, SMRT_NNP also_RB binds_NNS ERβ_NNP in_IN the_DT presence_NN of_IN estrogens_NNS ,_,
        but_CC we_PRP have_VBP not_RB explored_JJ the_DT structural_JJ features_NNS that_WDT
        promote_VBP this_DT interaction_NN ._. Intriguingly_NNP ,_, human_JJ SMRT_NNP contains_VBZ
        a_DT sequence_NN insertion_NN at_IN the_DT position_NN of_IN the_DT hydrophobic_JJ
        pair_NN in_IN the_DT N-C_NNP oR_NN β-box_JJ ,_, which_WDT apparently_RB leads_VBZ to_TO deletion_NN
        of_IN both_DT residues_NNS (_( N-C_NNP oR_NN /_NN RMLS_NNP >_NN SMRT_NNP /_NN RLqagvmaS_NNP )_) [_NN 52_CD ]_NN ._.
        Perhaps_RB SMRT_NNP contains_VBZ a_DT different_JJ NR_NNP interacting_VBG motif_NN or_CC
        the_DT N-C_NNP oR_NN NR_NNP box_NN sequence_NN may_MD be_VB more_RBR complex_JJ than_IN we_PRP have_VBP
        initially_RB reported_VBN here_RB ._.
      
      
        Methods_NNP
        
          Materials_NNS
          Estradiol_NNP ,_, diethylstilbestrol_NN (_( DES_NNP )_) ,_, tamoxifen_NN ,_,
          genistein_NN ,_, coumestrol_NN ,_, thyroid_NN hormone_NN ,_, retinoic_JJ acid_NN and_CC
          trichostatin_NN A_DT (_( TSA_NNP )_) were_VBD purchased_VBN from_IN Sigma_NNP (_( St_NNP ._.
          Louis_NNP ,_, MO_NNP )_) ._. ICI_NNP 182_CD ,_, 780_CD was_VBD a_DT gift_NN from_IN Alan_NNP Wakeling_NNP
          (_( Astra_NNP /_NN Zeneca_NNP Pharmaceuticals_NNP ,_, Macclesfield_NNP UK_NNP )_) ._.
          Raloxifene_NNP was_VBD a_DT gift_NN from_IN Stefan_NNP Nilsson_NNP (_( KaroBio_NNP AB_NNP ,_,
          Huddinge_NNP ,_, Sweden_NNP )_) ._. Peptides_NNP were_VBD synthesized_JJ at_IN the_DT
          Biomolecular_NNP Resource_NNP Center_NNP at_IN UCSF_NNP ._.
          The_DT following_VBG plasmids_NNS (_( pSG_NN 5_CD -_: ERα_NNP ,_, pSG_NN 5_CD -_: ERβ_NNP (_( amino_JJ
          acids_NNS 1_CD -_: 530_CD )_) [_NN 31_CD ]_NN ,_, pGEX-N-CoR_JJ and_CC pGEX-SMRT_JJ [_NN 39_CD ]_NN ,_,
          VP_NNP 16_CD -_: TRβ_NNP and_CC Gal-_NNP N-C_NNP oR_NN [_NN 16_CD ]_NN ,_, GST-N-CoR_NNP fusions_NNS [_NN 17_CD ]_NN
          ,_, ERE-LUC_NNP ,_, GK_NNP 1_CD /_NN Gal_NNP 4_CD responsive_JJ reporter_NN and_CC Gal-_NNP ERα_NNP LBD_NNP [_NN
          53_CD ]_NN ,_, pM-D_JJ 2_CD ,_, pM-D_JJ 47_CD ,_, pM-F_JJ 6_CD [_NN 46_CD ]_NN )_) have_VBP been_VBN previously_RB
          described_VBN ._. VP_NNP 16_CD -_: ERβ_NNP LBD_NNP and_CC Gal-_NNP ERβ_NNP LBD_NNP contain_VB human_JJ ERβ_NNP
          sequences_NNS and_CC were_VBD gifts_NNS from_IN Dr_NNP ._. Dale_NNP Leitmann_NNP
          (_( University_NNP of_IN California_NNP ,_, San_NNP Francisco_NNP )_) ._. VP_NNP 16_CD -_: RAR-LBD_NNP
          was_VBD a_DT gift_NN from_IN Dr_NNP ._. David_NNP Moore_NNP ,_, Baylor_NNP ,_, Houston_NNP ,_, Texas_NNP ._.
          Gal-_NNP GRIP_NNP 1_CD NR_NNP box_NN (_( 1_CD ,_, 2_CD ,_, 3_LS )_) fusion_NN (_( amino_JJ acids_NNS 610_CD -_: 770_CD )_) was_VBD
          prepared_VBN by_IN PCR_NNP amplification_NN of_IN the_DT appropriate_JJ region_NN
          of_IN GRIP_NNP 1_CD (_( primers_NNS obtained_VBN from_IN Biomolecular_NNP Resource_NNP
          Center_NNP ,_, UCSF_NNP )_) containing_VBG EcoRI_NNP and_CC SalI_NNP sites_NNS ,_, the_DT PCR_NNP
          fragment_NN was_VBD digested_VBN with_IN these_DT enzymes_NNS and_CC subcloned_JJ
          into_IN the_DT pM_NN GAL_NNP 4_CD expression_NN vector_NN (_( Clontech_NNP
          Laboratories_NNPS ,_, Inc_NNP ._. Palo_NNP Alto_NNP ,_, CA_NNP )_) ._. VP_NNP 16_CD -_: ERβ_NNP mutations_NNS and_CC
          Gal-_NNP N-C_NNP oR_NN mutations_NNS were_VBD prepared_VBN using_VBG standard_JJ
          PCR-based_NNP site_NN directed_VBD mutagenesis_NNS (_( Quickchange_NNP Kit_NNP ,_,
          Stratagene_NNP ,_, La_NNP Jolla_NNP ,_, CA_NNP )_) and_CC confirmed_VBN by_IN sequencing_VBG ._.
          The_DT GAL_NNP 4_CD -_: β_NN box_NN fusion_NN was_VBD prepared_VBN by_IN synthesizing_VBG
          oligonucleotides_NNS corresponding_JJ to_TO the_DT β-box_JJ sequence_NN with_IN
          engineered_VBN EcoRI_NNP and_CC SalI_NNP restriction_NN sites_NNS ._. Annealed_NNP and_CC
          phosphorylated_JJ double_RB stranded_VBN oligonucleotide_NN was_VBD
          subcloned_JJ into_IN the_DT appropriate_JJ sites_NNS in_IN the_DT PM_NNP
          vector_NN ._.
        
        
          Bacterial_NNP Protein_NNP Expression_NNP and_CC GST_NNP Pulldown_NNP
          Assays_NNP
          GST-fusions_NNP were_VBD expressed_VBN in_IN E_NNP ._. Coli_NNP BL_NNP 21_CD [_NN 28_CD ]_NN ._.
          Cultures_NNP were_VBD grown_VBN to_TO OD_NNP 600_CD 1_CD ._. 5_CD at_IN room_NN temperatures_NNS
          (_( approximately_RB 22_CD °_NN C_NNP )_) and_CC protein_NN production_NN was_VBD initiated_VBN
          by_IN addition_NN of_IN IPTG_NNP to_TO 1_CD mM_NN ._. After_IN four_CD hours_NNS ,_, bacterial_JJ
          pellets_NNS were_VBD obtained_VBN ,_, resuspended_JJ in_IN 20_CD mM_NN HEPES_NNP pH_NN 7_CD ._. 9_CD /_NN
          80_CD mM_NN KCl_NNP /_NN 6_CD mM_NN MgCl_NNP 
          2_CD /_NN 1_CD mM_NN Dithiothreitol_NNP /_NN 1_CD mM_NN ATP_NNP /_NN 0_CD ._. 2_LS mM_NN
          phenylmethylsulfonyl_NN fluoride_NN and_CC protease_NN inhibitors_NNS and_CC
          sonicated_JJ ._. Debris_NNP was_VBD pelleted_JJ by_IN centrifugation_NN in_IN an_DT
          ss_NNS 34_CD rotor_NN for_IN 1_CD hour_NN at_IN 12_CD ,_, 000_CD rpm_NN ._. The_DT supernatant_NN was_VBD
          incubated_JJ with_IN glutathione_NN sepharose_NN 4_CD B_NNP beads_NNS (_( Amersham_NNP
          Pharmacia_NNP Biotech_NNP AB_NNP ,_, Uppsala_NNP ,_, Sweden_NNP )_) and_CC washed_VBN as_RB
          previously_RB described_VBD ._. Protein_NNP preparations_NNS were_VBD stored_VBN at_IN
          -_: 20_CD °_NN C_NNP in_IN 20_CD %_NN glycerol_NN ._.
          Labeled_NNP ERs_NNP were_VBD produced_VBN using_VBG coupled_VBN 
          in_IN vitro_NN transcription-translation_JJ
          (_( TNT_NNP kit_NN ,_, Promega_NNP ,_, Madison_NNP ,_, Wisconsin_NNP )_) ._. Assays_NNP were_VBD
          carried_VBN out_IN in_IN a_DT volume_NN of_IN 150_CD μl_NN that_WDT contained_VBD 137_CD ._. 5_LS μl_NN
          of_IN ice-cold_JJ protein_NN binding_JJ buffer_NN (_( PBB_NNP )_) along_IN with_IN 10_CD μl_NN
          of_IN GST-bead_NNP slurry_NN corresponding_JJ to_TO 3_CD μg_NN of_IN fusion_NN
          protein_NN ,_, 1_CD μl_NN of_IN 
          in_IN vitro_NN translated_VBN protein_NN and_CC
          1_CD ._. 5_CD μl_NN of_IN ligand_NN or_CC vehicle_NN and_CC /_NN or_CC peptides_NNS or_CC vehicle_NN ._.
          PBB_NNP was_VBD freshly_RB prepared_VBN in_IN 24_CD ml_NN aliquots_NNS composed_VBN of_IN 20_CD
          ml_NN A-_NNP 150_CD (_( 20_CD mM_NN Hepes_NNP ,_, 150_CD mM_NN KCl_NNP ,_, 10_CD mM_NN MgCl_NNP 2_CD and_CC 1_CD %_NN
          glycerol_NN )_) ,_, and_CC 2_CD ml_NN each_DT of_IN phosphate_NN buffered_JJ saline_NN
          supplemented_JJ ,_, respectively_RB ,_, with_IN 1_CD %_NN Triton_NNP X-_NNP 100_CD and_CC 1_CD %_NN
          NP-_NNP 40_CD ._. PMSF_NNP ,_, DTT_NNP ,_, BSA_NNP and_CC protease_NN inhibitor_NN cocktail_NN
          (_( Novagen_NNP )_) were_VBD added_VBN to_TO 0_CD ._. 1_CD mM_NN ,_, 1_CD mM_NN ,_, 2_CD μg_NN /_NN ml_NN and_CC 1_CD /_NN 1000_CD
          dilution_NN respectively_RB ._. The_DT mix_NN was_VBD incubated_JJ for_IN two_CD
          hours_NNS in_IN the_DT cold_JJ room_NN with_IN gentle_JJ agitation_NN ,_, the_DT beads_NNS
          were_VBD pelleted_JJ by_IN spinning_JJ briefly_NN on_IN a_DT bench_NN top_JJ
          Eppendorf_NNP centrifuge_NN ,_, washed_VBD four_CD times_NNS with_IN PBB_NNP
          containing_VBG no_DT BSA_NNP ,_, and_CC the_DT pellet_NN was_VBD dried_VBN under_IN vacuum_NN
          for_IN twenty_CD minutes_NNS ._. Labeled_NNP protein_NN was_VBD subjected_VBN to_TO
          SDS-polyacrylamide_NNP gel_NN electrophoresis_NNS and_CC
          autoradiography_NN ._.
        
        
          Transfections_NNP
          HeLa_NNP cells_NNS were_VBD grown_VBN in_IN DME_NNP /_NN F-_NNP 12_CD Ham_NNP 's_POS 1_CD :_: 1_CD mix_NN ,_,
          without_IN phenol_NN red_JJ (_( Sigma_NNP )_) containing_VBG 10_CD %_NN iron_NN
          supplemented_JJ calf_NN serum_NN (_( Sigma_NNP )_) and_CC pen-strep_JJ ._. Cells_NNP were_VBD
          transfected_JJ by_IN electroporation_NN [_NN 28_CD ]_NN ._. Transfections_NNP
          contained_VBD 2_CD μg_NN of_IN luciferase_NN and_CC actin-β-galactosidase_JJ
          reporters_NNS and_CC ,_, where_WRB indicated_VBD ,_, 1_CD μg_NN of_IN ER_NNP ,_, VP_NNP 16_CD -_: fusion_NN
          protein_NN or_CC GAL_NNP 4_CD -_: fusion_NN protein_NN expression_NN vectors_NNS or_CC
          empty_JJ vector_NN controls_NNS ._. Luciferase_NNP and_CC β-galactosidase_JJ
          activities_NNS were_VBD measured_VBN using_VBG luciferase_NN (_( Promega_NNP ,_,
          Madison_NNP ,_, WI_NNP )_) and_CC Galacto-_NNP Light_NNP assay_NN systems_NNS (_( Tropix_NNP ,_,
          Bedford_NNP ,_, MA_NNP )_) ._.
        
      
      
        List_NN of_IN Abbreviations_NNP
        AIB_NNP 1_CD Amplified_NNP in_IN breast_NN cancer_NN 1_CD ._.
        AF-_NNP 1_CD Activation_NNP function_NN 1_CD
        AF-_NNP 2_CD Activation_NNP function_NN 2_CD
        AP-_NNP 1_CD Activator_NNP protein_NN 1_CD
        CARM_NNP 1_CD Coactivator_NNP associated_VBN arginine_NN methyl-transferase_JJ
        1_CD ._.
        CBP_NNP CREB_NNP binding_JJ protein_NN ._.
        CRE_NNP Cyclic_NNP Amp_NNP response_NN element_NN
        DAX_NNP Dosage_NNP sensitive_JJ sex_NN reversal_NN adrenal_NN hyperplasia_NN
        congenital_NN critical_JJ region_NN on_IN the_DT X-_NNP chromosome_NN ,_, region_NN
        1_CD ._.
        DES_NNP Diethylstilbestrol_NNP
        DNA_NNP Deoxyribonucleic_NNP acid_NN
        DBD_NNP DNA_NNP binding_JJ domain_NN
        TNFα_NNP Tumor_NNP necrosis_NNS factor_NN alpha_NN 1_CD
        E_NNP 2_CD Estradiol_NNP
        ERα_NNP Estrogen_NNP receptor_NN alpha_NN
        ERβ_NNP Estrogen_NNP receptor_NN beta_NN
        ERE_NNP ,_, Estrogen_NNP response_NN element_NN
        GRIP_NNP 1_CD Glucocorticoid_NNP receptor_NN interacting_VBG protein_NN 1_CD ;_:
        GST_NNP Glutathione_NNP S-_NNP transferase_NN
        H_NNP Helix_NNP
        HAT_NNP Histone_NNP acetyl-transferase_JJ
        HET-SAFB_NNP Hsp_NNP 27_CD -_: ERE-TATA_NNP binding_JJ protein_NN /_NN scaffold_NN
        attachment_NN factor_NN B_NNP ._.
        HDAC_NNP Histone_NNP de-acetylase_JJ
        ID_NNP Interaction_NNP domain_NN ._.
        LBD_NNP Ligand_NNP binding_JJ domain_NN
        NR_NNP Nuclear_NNP receptor_NN
        NTD_NNP Amino_NNP terminal_NN domain_NN
        N-C_NNP oR_NN Nuclear_NNP receptor_NN corepressor_NN
        PBS_NNP Phosphate_NNP buffered_JJ saline_NN
        PCR_NNP Polymerase_NNP chain_NN reaction_NN
        PERC_NNP PGC-_NNP 1_CD related_VBN estrogen_NN receptor_NN coactivator_NN
        PGC-_NNP 1_CD Peroxisome_NNP proliferator_NN activated_VBN receptor_NN gamma_NN
        coactivator_NN 1_CD ._.
        RAR_NNP Retinoic_NNP acid_NN receptor_NN
        REA_NNP Repressor_NNP of_IN estrogen_NN receptor_NN activity_NN
        RIP_NNP 140_CD Receptor_NNP interacting_VBG protein_NN of_IN 140_CD Kd_NNP
        SDS-PAGE_NNP Sodium_NNP dodecyl_NN sulfate_NN polyacrylamide_NN gel_NN
        electrophoresis_NNS
        SMRT_NNP Silencing_NNP Mediator_NNP of_IN Retinoid_NNP and_CC Thyroid_NNP
        Responsive_NNP transcription_NN ._.
        SERM_NNP Selective_NNP estrogen_NN receptor_NN modulator_NN (_( s_VBZ )_)
        SHP_NNP Short_JJ heterodimer_NN partner_NN
        SRC-_NNP 1_CD Steroid_NNP receptor_NN coactivator_NN 1_CD
        TR_NNP Thyroid_NNP receptor_NN
        TRAP_NNP 220_CD TR_NNP associated_VBN protein_NN of_IN 200_CD Kd_NNP ._.
      
      
        Competing_VBG Interests_NNP
        
        PW_NNP None_NN declared_VBD ._.
        
        CV_NNP None_NN declared_VBD
        
        PN_NNP None_NN declared_VBD
        
        RHP_NNP Jr_NNP ._. None_NN declared_VBD ._.
        
        AM_NNP Since_IN the_DT studies_NNS were_VBD performed_VBN ,_,
        has_VBZ moved_VBN to_TO Plexxikon_NNP ,_, a_DT company_NN with_IN interests_NNS in_IN protein_NN
        structure_NN ._.
        
        BLW_NNP Since_IN the_DT studies_NNS were_VBD performed_VBN ,_,
        has_VBZ moved_VBN to_TO Plexxikon_NNP ,_, a_DT company_NN with_IN interests_NNS in_IN protein_NN
        structure_NN ._.
        
        JDB_NNP has_VBZ proprietary_JJ interests_NNS in_IN ,_, and_CC
        serves_VBZ as_IN consultant_NN and_CC deputy_NN director_NN to_TO Karo_NNP Bio_NNP AB_NNP ,_, a_DT
        Swedish_JJ company_NN that_WDT develops_VBZ pharmaceuticals_NNS that_WDT target_NN
        NRs_NNP ._.
        
        PJK_NNP has_VBZ significant_JJ financial_JJ interests_NNS
        in_IN ,_, and_CC is_VBZ a_DT consultant_NN and_CC former_JJ director_NN of_IN ,_, Karo_NNP Bio_NNP
        AB_NNP ._.
      
      
        Authors_NNP Contributions_NNP
        PW_NNP Conceived_NNP and_CC directed_VBD the_DT studies_NNS ,_, wrote_VBD the_DT paper_NN ,_,
        performed_VBN plasmid_NN constructions_NNS and_CC transfection_NN
        studies_NNS ._.
        CV_NNP Performed_NNP transfection_NN ,_, mutagenesis_NNS and_CC GST_NNP pulldown_NN
        experiments_NNS under_IN guidance_NN of_IN PW_NNP ._.
        PN_NNP Performed_NNP transfection_NN ,_, mutagenesis_NNS and_CC GST_NNP pulldown_NN
        experiments_NNS under_IN guidance_NN of_IN PW_NNP ._.
        RHP_NNP Jr_NNP ._. Provided_VBN intellectual_JJ input_NN in_IN the_DT study_NN
        design_NN ._.
        AM_NNP ._. Expressed_NNP GST_NNP N-C_NNP oR_NN fragments_NNS for_IN pulldown_NN studies_NNS
        with_IN ERβ_NNP ._.
        BW_NNP Designed_NNP bacterial_JJ expression_NN vectors_NNS for_IN N-C_NNP oR_NN
        fragments_NNS ,_, cloned_VBN cDNA_NN fragments_NNS for_IN GST-N-CoR_NNP expression_NN
        vectors_NNS and_CC provided_VBN intellectual_JJ input_NN into_IN the_DT study_NN
        design_NN ._.
        JDB_NNP ._. Directed_NNP studies_NNS of_IN NR_NNP interactions_NNS with_IN N-C_NNP oR_NN and_CC
        provided_VBN intellectual_JJ input_NN into_IN study_NN design_NN ._.
        PJK_NNP ._. Co-directed_NNP studies_NNS along_IN with_IN PW_NNP and_CC provided_VBN
        intellectual_JJ input_NN into_IN study_NN design_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
